Why Amgen (AMGN) Dipped More Than Broader Market Today

In the latest trading session, Amgen (AMGN) closed at $295.98, marking a -1.71% move from the previous day. This change lagged the S&P 500's daily loss of 0.53%. At the same time, the Dow lost 0.71%, and the tech-heavy Nasdaq lost 0.93%. Coming into today, shares of the world's largest biotech drugmaker had gained 5% in the past month. In that same time, the Medical sector gained 3.64%, while the S&P 500 gained 1.13%. The upcoming earnings release of Amgen will be of great interest to investors. The company's earnings report is expected on November 4, 2025. It is anticipated that the company will report an EPS of $5.01, marking a 10.22% fall compared to the same quarter of the previous year. In the meantime, our current consensus estimate forecasts the revenue to be $8.94 billion, indicating a 5.14% growth compared to the corresponding quarter of the prior year. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of $21.09 per share and revenue of $35.65 billion, indicating changes of +6.3% and +6.65%, respectively, compared to the previous year. Investors might also notice recent changes to analyst estimates for Amgen. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. The Zacks Rank system, stretching from #1 (Strong Buy) to #5 (Strong Sell), has a noteworthy track record of outperforming, validated by third-party audits, with stocks rated #1 producing an average annual return of +25% since the year 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.09% lower. Right now, Amgen possesses a Zacks Rank of #3 (Hold). In the context of valuation, Amgen is at present trading with a Forward P/E ratio of 14.28. This represents a discount compared to its industry average Forward P/E of 20.42. We can also see that AMGN currently has a PEG ratio of 2.66. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. As the market closed yesterday, the Medical - Biomedical and Genetics industry was having an average PEG ratio of 1.67. The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 92, this industry ranks in the top 38% of all industries, numbering over 250. The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness Zacks.com to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Beyond Nvidia: AI's Second Wave Is HereThe AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. Little-known AI firms tackling the world's biggest problems may be more lucrative in the coming months and years.See "2nd Wave" AI stocks now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Amgen Inc. (AMGN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks